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LEARNING OBJECTIVES
After completing this course, the reader will be able to:
1. Use the correlation of all data from clinical, imaging, and histopathologic observations by a multidisciplinary
tumor board in the prognosis of patients with soft tissue sarcoma.
2. Interpret the prognostic value of histologic response to chemotherapy in soft tissue sarcoma in contrast to its value
in osteosarcoma and Ewing’s sarcoma.
3. Evaluate the profound histologic alterations induced by neoadjuvant chemotherapy in soft tissue sarcomas.
Access and take the CME test online and receive 1 AMA PRA Category 1 Credit™ at CME.TheOncologist.comCME
ABSTRACT
Histologic response to chemotherapy is generally regarded
as an independent prognostic variable in bone sarcomas,
both osteosarcoma and Ewing’s sarcoma. In soft tissue
sarcomas, however, descriptions of histologic alterations
from chemotherapy and correlative outcome studies are
much more limited. Herein we report clinicopathological
findings from a homogeneously treated group of 31 pa-
tients with tumor stage T2 grade 3 extremity soft tissue
sarcomas treated with the same neoadjuvant chemother-
apy followed by surgical excision, treated by the same
medical oncologist and orthopedic surgeon. Histologic re-
sponse to therapy was evaluated by multiple parameters
using a semiquantitative grading system. Based upon the
percentage of post-treatment viable tumor, tumors were
arbitrarily categorized similarly to Huvos score as show-
ing excellent (<5% viability), moderate (6%–49% viabil-
ity), or poor (>50% viability) responses. Nineteen percent
had excellent, 10% had moderate, and 71% had poor re-
sponses. These histologic response groups did not corre-
late with overall or event-free survival. For example, of
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the 22 patients showing a “poor” response, 13 were
cured. Similarly, other histologic parameters, including
percentages of necrosis, fibrosis/hyalinization, and cel-
lular degeneration, did not correlate with outcome.
Chemotherapy induces profound tissue alterations in
soft tissue sarcomas. However, histologic alteration by
itself may not be a reliable prognostic variable. Corre-
lation of all data from clinical, imaging, and pathologi-
cal observations by a multidisciplinary tumor board
should have greater prognostic value than histology
alone. Finally, although the histologic grading system
used in this study could not be validated, the criteria we
employed are simple and reproducible and take into ac-
count the major histologic patterns seen after therapy,
and would be amenable for use in future studies. The On-
cologist 2008;13:451–458
INTRODUCTION
Chemotherapy, while still controversial, is commonly
employed in treating high-grade soft tissue sarcomas. Al-
though studies have shown that the use of adjuvant doxo-
rubicin-based therapy leads to a longer time to local and
distant recurrence [1] and a longer overall recurrence-
free survival time [1, 2], no statistically significant dif-
ference in overall survival was demonstrated in a large
meta-analysis [1]. Large, high-grade, localized tumors
are treated with neoadjuvant chemotherapy followed by
complete surgical excision and postoperative radiother-
apy in many sarcoma centers in this country. Important
benefits of preoperative chemotherapy include: (a) re-
ducing tumor volume and cellular viability to facilitate
limb-salvage surgery [3], (b) putatively eliminating mi-
crometastatic disease, and (c) permitting in vivo assess-
ment of treatment effect both by change in size and/or
imaging characteristics of the tumor as well as by histo-
logic response. Histologic response to neoadjuvant che-
motherapy has been shown to be an independent
prognostic variable in bone sarcomas, both osteosarcoma
and Ewing’s sarcoma [4 –9]. Intriguingly, not all studies
have demonstrated a correlation of histology with treat-
ment and survival in osteosarcoma [10, 11], challenging
the emphasis placed on histologic response as the key
treatment-related predictive factor in osteosarcoma [10].
In soft tissue sarcoma, correlations between histologic
alteration and long-term outcome are limited to only a
handful of studies with opposing results [12–15]. Also,
in two of these studies [13, 14], the patients had preop-
erative radiotherapy and/or intra-arterial infusions in ad-
dition to i.v. chemotherapy, which certainly altered the
tissue effects of systemic chemotherapy alone. In order
to study the histologic effect of systemic neoadjuvant
chemotherapy in soft tissue sarcoma and to see if it might
have prognostic value, we analyzed a series of common
phenotype, localized, high-grade, extremity, soft tissue
sarcomas treated at our institution over a 10-year period
by the same medical and orthopedic oncologists.
MATERIALS AND METHODS
Case Selection
The study was conducted with approval by the institutional
review board at our institution. Search of the pathology da-
tabase for all sarcoma cases during the years 1994–2003
yielded approximately 3,000 entries. All entries were care-
fully screened to include only high-grade soft tissue sarco-
mas of common phenotypes limited to the extremities. We
excluded a priori all cases of clear cell sarcoma, Ewing’s
sarcoma, and pediatric rhabdomyosarcoma in order to
maintain a uniform series of conventional adult-type soft
tissue sarcomas. We then consulted the clinical database to
limit the cases only to patients with primary tumors, local-
ized at the time of diagnosis, 5 cm, and who had been
treated with systemic neoadjuvant doxorubicin and ifos-
famide (without preoperative radiotherapy) and primary
surgical excision at our institution. All surgical operations
were performed by Dr. Sybil Biermann and all chemother-
apy was supervised by Dr. Laurence Baker.
Imaging Studies
All patients were studied preoperatively with chest com-
puted tomography (CT) and gadolinium-enhanced mag-
netic resonance imaging (MRI), imaging the entirety of the
compartment in which the tumor was contained. Pre- and
post-treatment tumor sizes were tabulated from the radiol-
ogy records based upon results of imaging studies. Clinical
response categories were then determined based upon the
Response Evaluation Criteria in Solid Tumors (RECIST)
[16]. Assessment of primary response and detection of dis-
tant metastasis were done in accordance with National
Comprehensive Cancer Center Network soft tissue guide-
lines.
Chemotherapy
A standard University of Michigan protocol for sarcoma
chemotherapy was followed [17]. All patients were treated
in the outpatient clinic and received doxorubicin (60 mg/
m2) via continuous i.v. infusion and ifosfamide (2–3 g/m2)
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as 2-hour infusions with mesna support. All therapy was ad-
ministered over 72 hours every 21 days. All patients re-
ceived postchemotherapy G-CSF. Almost all patients
received the intended four cycles of therapy. The planned
surgery took place 21–28 days following day 1 of the last
cycle of chemotherapy.
Surgical Technique
Patients underwent wide resection of the tumor bed and ex-
cision of biopsy tracts. In selected cases, narrow or micro-
scopically positive margins were accepted to spare
neurovascular structures. All cases had all gross tumor re-
sected at a minimum.
Pathology
Gross
The specimens were dissected in the conventional manner.
Following measurement, the marginal surface was inked
and the tumors were serially transected. Gross estimation of
percent necrosis was recorded, and multiple sections were
taken from the solid areas as well as from the margins. The
tumors were sampled with an average of one section per
centimeter of the tumor’s greatest dimension.
Histologic Grading of Response
The tumors were systematically evaluated with a semiquan-
titative grading system. In every case, we determined the
percent areas of viable tumor, necrotic tumor, and fibrous/
hyalinized stroma such that the sum of these three compo-
nents was equal to 100%. We estimated the percentage of
cells demonstrating degenerative changes, defined by large,
bizarre, often multinucleated cells with smudged and/or
vacuolated chromatin. In addition, we tabulated the pres-
ence or absence of mitotic figures, hemosiderosis, xan-
thogranulomatous and lymphocytic inflammation, and
cystic hemorrhagic spaces, and whether or not the margins
were positive. These criteria were tabulated independently
by two pathologists (DL, MK), and any differences were re-
solved by consensus at a two-headed microscope. Based
upon the results, the tumors were arbitrarily categorized as
having an excellent response when5% viable tumor was
present, a moderate response for 6%–49% viable tumor, or
a poor response for50% viable tumor.
Clinical Outcome
All patients had been treated in our sarcoma center, and
treatment and follow-up data were attained from the medi-
cal records. In selected cases, the social security death index
was queried. Negative events defined as metastasis, local
recurrence, or death resulting from disease, along with the
time interval from initial diagnosis to the specific event and
the date of last follow-up, were tabulated.
Statistics
Kaplan–Meier survivorship plots were constructed from
the data comparing clinical or pathological variables with
event-free survival. Statistical comparisons were calculated
with the log-rank and Wilcoxon methods. A p-value of
.05 was regarded as significant.
RESULTS
General Data
Thirty-one patients met the eligibility criteria, consisting of
11 women and 20 men with a median age of 57 years
(range, 7–76). All tumors were high-grade sarcomas based
on a two-scale system of low and high grades. Sixteen were
categorized as malignant fibrous histiocytoma/undifferen-
tiated pleomorphic sarcoma, five as synovial sarcoma, five
as liposarcoma (three pleomorphic, one dedifferentiated
and one unclassified liposarcoma), three as leiomyosar-
coma, and one each as fibrosarcoma and malignant periph-
eral nerve sheath tumor. Twenty-three tumors were situated
in a lower extremity, with the thigh representing the most
common site (14 tumors). Eight occurred in an upper ex-
tremity, with the upper arm being the most common site
(four tumors).
Pathology
There was excellent agreement between the two observers
regarding histology. There were three major architectural
patterns: (a) viable tumor, (b) necrotic tumor, and (c) fi-
brotic or hyalinized stroma (Fig. 1). Viable tumor varied
from seemingly unaffected cells to large, degenerated cells.
Nuclear and cytoplasmic expansion, smudged chromatin,
intranuclear vacuoles, and multinucleation accounted for
treatment-related degenerative changes (Fig. 2). The pro-
portions of degenerated cells varied from 5% in 19 tu-
mors, to 6%–49% in eight tumors, and to 50% in four
tumors. The median amount of fibrotic/hyalinized stroma
was 15%, but varied from 0% to 95%. Scattered, degener-
ated tumors cells were frequently present within these fi-
brotic/hyalinized areas (Fig. 1C), as were xanthogranu-
lomatous inflammation and hemosiderosis. Mitotic figures
were identified in all but four tumors, including within ar-
eas showing degenerative atypia. Of note, three of the four
tumors without mitotic figures had5% viable tumor. Cys-
tic hemorrhagic spaces were microscopically identified in
12 tumors. Based upon the percentage of viable tumor
within the post-treatment resection specimens, 19% were
categorized as having an excellent response, 10% were cat-
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egorized as moderate, and 71% were categorized as poor.
Ten tumors had microscopically positive margins.
Imaging Studies
The median pretreatment tumor size was 7.6 cm (range,
5–22). Paired pre- and post-treatment measurements were
documented in 21 cases such that clinical response based
upon the RECIST could be determined. Among the excel-
lent histologic responders, one (20%) had a partial response
and four (80%) had stable disease. The single patient with
data who had a moderate histologic response had stable dis-
ease, while the poor response group (n 15) showed partial
responses in 13%, stable disease in 67%, and progressive
disease in 20%. There was no statistical correlation be-
tween clinical response by the RECIST and outcome.
Clinical Outcome
The median follow-up time was 50 months (mean, 52;
range, 5–145). Fifteen patients (48%) had a negative
event. Nine (29%) had distant metastases, one (3%) had
local recurrence only, and five (16%) had both local and
distant recurrences. Eleven patients (35%) died of their
disease. In the excellent response group, four patients
(67%) developed distant metastases, two of whom also
had local recurrences. Of these six patients, three died of
disease, one was alive with metastatic disease, and two
were alive without evidence of disease at last follow-up.
In the moderate response group, one patient developed
distant metastasis and died of disease, one was alive
without disease, and one died (etiology not known by us)
6 months after initial diagnosis. In the poor response
group, 10 patients (45%) had a negative event. Nine de-
veloped metastases, three of whom also had local recur-
rences, and one had only a local recurrence. Seven of
these 22 patients were dead of disease, one was alive with
Figure 1. Three major architectural patterns were present in sarcomas treated with neoadjuvant chemotherapy: viable tumor (A),
necrotic tumor (B), and fibrotic/hyalinized stroma (C). Note the single degenerated cell entrapped within hyalinized stroma. (He-
matoxylin and eosin, original magnification 400.)
Figure 2. Marked degenerative atypia characterized by large,
bizarre, often multinucleated cells with smudged and/or vacu-
olated chromatin was a common finding in tumors treated with
chemotherapy. (Hematoxylin and eosin, original magnifica-
tion400.)
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disease, 12 were alive with no evidence of disease, and
two were lost to follow-up: one who was alive at 7 years
and one who was dead, but of cause unknown to us 2
years after initial diagnosis.
Statistical Analyses
Utilizing Kaplan–Meier survival plots along with log-rank
and Wilcoxon statistics, there were no significant correla-
tions between the histologic response groups (excellent,
moderate, and poor) and overall or event-free survival
times (Fig. 3). Similarly, necrosis, fibrosis/hyalinization,
cellular degeneration, mitotic activity, inflammation, tumor
type, pretreatment size, upper versus lower extremity loca-
tion, age, sex, or clinical response based upon the RECIST
had no significant effect upon survival. There were no sig-
nificant differences in the time to development of a negative
event among the three response groups.
DISCUSSION
The application of neoadjuvant chemotherapy as a treat-
ment modality in cancer derives from animal studies that
demonstrate accelerated metastatic tumor growth following
surgical excision of the primary tumor, and that chemother-
apy is most effective in suppressing residual tumor growth
when given preoperatively [18, 19]. Post-treatment tumor
necrosis is regarded as a surrogate indicator of the effective-
ness of chemotherapy. While well-defined histopathologic
criteria for assessing therapy effect in osteosarcoma and
Ewing’s sarcoma have been devised [7, 20–22], few studies
have addressed this in soft tissue sarcoma [12, 13, 15, 23–
27]. And, although histologic response to chemotherapy is
generally, but not universally [10, 11], accepted as an im-
portant prognostic variable in bone sarcomas [4 –9], few
studies have addressed this issue in soft tissue sarcomas
[12–15, 27]. The aims of this study were therefore two-
fold—to describe the histologic findings and develop a
grading system for assessing response to therapy and to de-
termine if histologic response would predict clinical out-
come. We were able to devise a reproducible grading
system based upon our observations.
The study set consisted of a uniquely homogeneous
group of patients defined by very specific eligibility crite-
ria. All patients presented with localized, untreated primary
tumors limited to the extremities. All were high-grade,
common adult-type sarcomas. All patients were treated
with neoadjuvant i.v. doxorubicin plus ifosfamide chemo-
therapy without preoperative radiotherapy. In most of the
previous studies, patients had been treated with preopera-
tive radiotherapy and/or intra-arterial infusions in addition
to i.v. chemotherapy, which most certainly affected the his-
tology [13, 14, 23, 24], masking the effects of systemic che-
motherapy alone. In addition, in our study, all treatments
and operations were performed at a single institution by the
same orthopedic and medical oncologists, thus providing a
uniform treatment group.
By microscopic examination, the post-treatment tumor
specimens had three major tissue patterns consisting of vi-
able tumor, necrotic tumor, and stromal fibrosis/hyaliniza-
tion, which could be roughly quantified as percentages such
that the sum was equal to 100%. Based upon the amount of
viable tumor, we stratified the cases into excellent, moder-
ate, and poor response groups. We also observed and tabu-
Figure 3. Kaplan–Meier event-free survival plot comparing the excellent and moderate histologic response groups with the poor
response group. There was no significant difference.
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lated a number of other histologic parameters, including
cellular degeneration, mitotic activity, inflammation, and
hemorrhage. Although response to therapy has traditionally
been described in terms of percent tumor necrosis, we, like
other investigators [23–25], describe it in terms of percent
tumor viability. The advantage to this approach is that it
combines necrosis, a common finding in untreated sarco-
mas, with stromal fibrosis/hyalinization, a more specific
pattern associated with treatment effect, as elements of non-
viable tumor. Thus, percent viability should be a more ac-
curate portrayal of treatment effect than frank tumor
necrosis. Interestingly, mitotic activity was a common find-
ing in treated tumors, identified in all but four of our cases,
and was observed occasionally in markedly degenerated
cells, suggesting that these degenerated cells are not neces-
sarily terminal forms.
We were not able to demonstrate a correlation between
histologic alteration and clinical outcome. In fact, four of
the six patients with excellent responses based upon 5%
tumor viability progressed to distant metastatic disease. By
contrast, among the 22 patients with poor responses, 13
seemed to be cured. Similarly, the other histologic features
we evaluated, especially percentages of necrosis, fibrosis/
hyalinization, and degenerative cellular atypia, showed no
correlation with outcome. Nor did clinical response based
upon the RECIST, which in our experience have relatively
poor performance in the neoadjuvant setting. Although one
might intuitively assume that a good histologic response
translates into chemosensitivity, conventional histology
alone may not be the best indicator of this phenomenon. For
example, a given tumor may show an excellent clinical re-
sponse based upon the reduction in tumor volume, while the
histology continues to show mostly viable tumor. In this
case, histology would underestimate the level of response.
Conversely, a tumor may remain unchanged or even in-
crease in size while showing very little viable tumor. For
example, tumors with substantial collagenous or myxoid
stroma, and ones that acquire intratumoral hemorrhage or
edema during therapy, may show little change in size or
even increase in size despite an excellent histologic re-
sponse. In this case, imaging would underestimate the level
of response. Other imaging characteristics beyond simple
change in volume, such as decreased fluorodeoxyglucose
uptake by positron emission tomography [28], induction of
central necrosis with thickening of the pseudocapsule by
MRI [13], and reduction in tumor density as evidenced by
decreased Hounsfield units by CT [29], may prove to be
more accurate ways to assess treatment in vivo.
The percentage of favorable therapy-related histologic
responses in our series (19%) is lower than that reported in
most other series [12–15, 23–25, 27]. However, most of the
previous studies employed preoperative radiotherapy
and/or intra-arterial chemotherapy, which most certainly
accounted for the enhanced treatment effect. For example,
in the largest reported study of 496 patients [14], 52% had
either no residual tumor or 95% necrosis. In that study,
however, all patients had been treated with preoperative ra-
diotherapy and most had also been treated with intra-arte-
rial infusions in addition to systemic chemotherapy. In a
smaller study of 33 patients, Henshaw et al. [13] reported
76% of tumors having95% necrosis. Although none had
preoperative radiation, all patients had been treated with in-
tra-arterial cisplatin. Similarly, Schmidt et al. [23] reported
a higher percentage of tumors with good responses (defined
as15% viable tumor) present in 44% of their 25 cases, but
their patients also had intra-arterial chemotherapy. In a Ra-
diation Therapy Oncology Group trial [24], which em-
ployed aggressive preoperative chemo- and radiotherapy,
64% of the tumors showed substantial histologic responses
(25% viable tumor), including 27% with no viable tumor
identified. Among studies that employed only systemic
chemotherapy without preoperative radiotherapy or intra-
arterial chemotherapy, Menendez et al. [12] reported 39%
of 82 tumors with 95% necrosis, Jimenez et al. [25] re-
ported 21% of 29 tumors with good (15% viable tumor)
responses, Pezzi et al. [15] reported 48% of 27 patients with
“histologic evidence of response,” and Casper et al. [27] re-
ported 13% of 29 patients with90% necrosis.
Among the studies that reported histologic results, we
are aware of five that correlated them with long-term fol-
low-up. In the largest study by Eilber et al. [14], 95%
post-treatment necrosis was associated with a significant
survival advantage. Henshaw et al. [13] also reported a
longer survival time in patients with95% necrosis. Inter-
estingly however, among the four patients in that study who
developed metastatic disease, three had 95% necrosis.
Among the studies of preoperative systemic chemotherapy
alone, only Pezzi et al. [15] reported that histologic re-
sponse correlated with a significantly longer survival time,
while Casper et al. [27] provide less convincing evidence.
Similar to our findings, Menendez et al. [12], in a recent
study of 82 patients, could not demonstrate a correlation be-
tween histologic response and outcome, and concluded that
tumor necrosis following chemotherapy has no prognostic
value in soft tissue sarcoma.
CONCLUSIONS AND SUMMARY
We report our experience in a series of patients with stage
T2 grade 3 extremity soft tissue sarcomas treated with neo-
adjuvant chemotherapy. Chemotherapy induced profound
tissue changes including necrosis, fibrosis/hyalinization,
and marked cytological degeneration, and one fifth of our
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cases had an excellent histological response as evidenced
by 5% viable tumor. As a result of our observations, we
devised a semiquantitative grading system based upon per-
centages of viable tumor, necrotic tumor, and fibrosis/
hyalinization. Clinicopathological correlation between
histologic response and outcome using these parameters,
however, failed to demonstrate a relation. The facts that
four of six patients in the excellent response group devel-
oped metastases and that 13 of 22 patients in the poor re-
sponse group were seemingly cured imply that histologic
response by itself may not be a reliable predictor of behav-
ior. Although other investigators have proposed including
pathological response as a parameter in determining which
patients receive additional chemotherapy [15], we cannot
recommend this practice based upon histology alone. As in
all previous studies that correlated systemic chemotherapy
effect on the primary tumor and outcome, ours is limited by
inadequate numbers of patients. A much larger cohort, as
might be achievable in a multidisciplinary clinical trial,
would be required to achieve a more conclusive result. We
are prospectively evaluating histologic response in our cur-
rent neoadjuvant study of doxorubicin plus ifosfamide ver-
sus gemcitabine plus docetaxel. Although the grading
system we devised—which quantifies the three major pat-
terns of histologic alteration seen after chemotherapy of vi-
able tumor, necrotic tumor, and fibrosis/hyalinization such
that the sum equals 100%, as well as other parameters such
as cellular degeneration—could not be validated, we find it
easy to use and reproducible. We propose it as a potentially
new way of reporting pathologic tumor response in adult
soft tissue sarcomas, acknowledging that future studies
may face the same difficulty with validation that we did, es-
pecially because there is no definitive proof of the efficacy
of chemotherapy in localized tumors. Finally, because his-
tology does not always correlate with clinical response,
evaluation of all data by a multidisciplinary tumor board,
including clinical, imaging, and histologic data, should pro-
vide greater predictive value than histology alone.
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